EUVIMEDEUVIMED entdecken
Übersichtsarbeit

GLP-1 receptor agonists: emerging therapeutic potential in psoriasis management — current evidence and future outlook

Nabiha Atiquzzaman, Nicole Razdolsky, Mayur S Parmar

European Journal of Clinical Pharmacology · 2025

DOI: 10.1007/s00228-025-03898-4 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Clinical Pharmacology, 2025. Verfasst von Nabiha Atiquzzaman und 2 weiteren Autor:innen. Beteiligte Einrichtung: Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL, USA. Hauptthemen laut MEDLINE: Psoriasis, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Psoriasis is a chronic inflammatory skin disease driven by immune dysregulation and often exacerbated by metabolic comorbidities. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for type 2 diabetes mellitus (T2DM) and weight management, have emerged as a promising treatment due to their anti-inflammatory and immunomodulatory properties. PURPOSE: This review evaluates the clinical efficacy, mechanisms of action, and limitations of GLP-1RAs, such as liraglutide, exenatide, and semaglutide, in the management of psoriasis. METHODS: A comprehensive literature review was conducted, including evidence from case reports, randomized controlled trials, prospective cohorts, and experimental studies, to assess the role of GLP-1RAs in psoriasis treatment. RESULTS: Evidence suggests that GLP-1RAs mitigate psoriasis severity through systemic effects, including weight loss and improved glycemic control, and local immunomodulation, such as the regulation of invariant natural killer T (iNKT) cells and AMPK activation in psoriatic plaques. These benefits are particularly notable in patients with coexisting metabolic conditions. However, the existing evidence is limited by small cohort sizes, heterogeneous patient populations, and confounding effects of concurrent therapies, limiting its generalizability. CONCLUSION: GLP-1RAs offer a novel integrative approach to managing psoriasis by targeting both inflammatory and metabolic pathways. Larger, long-term randomized controlled trials are needed to validate their efficacy, optimize dosing, and determine their role as standalone or adjunctive therapies, particularly in patients without metabolic comorbidities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisGlucagon-Like Peptide-1 Receptor AgonistsHumansLiraglutideAnimalsExenatideGlucagon-Like PeptidesGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

DermatologyExenatideGLP-1 receptor agonistLiraglutidePsoriasis managementSemaglutide

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsLiraglutideExenatideGlucagon-Like PeptidesGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL, USA.
  • Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Tampa Bay Regional Campus, Clearwater, FL, USA.
  • Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Tampa Bay Regional Campus, Clearwater, FL, USA. mparmar@nova.edu.

Zitieren

APA

Atiquzzaman, N., Razdolsky, N., & Parmar, M. S. (2025). GLP-1 receptor agonists: emerging therapeutic potential in psoriasis management — current evidence and future outlook. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-025-03898-4

Vancouver

Atiquzzaman N, Razdolsky N, Parmar MS. GLP-1 receptor agonists: emerging therapeutic potential in psoriasis management — current evidence and future outlook. European Journal of Clinical Pharmacology. 2025. doi:10.1007/s00228-025-03898-4

BibTeX
@article{Atiquzzaman2025,
  author = {Atiquzzaman, Nabiha and Razdolsky, Nicole and Parmar, Mayur S},
  title = {GLP-1 receptor agonists: emerging therapeutic potential in psoriasis management — current evidence and future outlook},
  journal = {European Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1007/s00228-025-03898-4}
}
Kostenlos starten →